Artiva Biotherapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Artiva Biotherapeutics (ARTV) with a Buy rating and $20 price target Artiva is a clinical stage biotechnology company developing natural killer cells for autoimmune diseases and cancers, the analyst tells investors in a research note. The firm says ongoing clinical trials for autoimmune diseases address a large potential opportunity for AlloNK, the company’s lead product candidate. Other companies and academic studies validate approaching autoimmune diseases with B-cell depletion, contends H.C. Wainwright.